NOV 15, 2018 11:01 AM PST

A Subclass of Anti-Aging Compounds Serves as Alzheimer's Drug Candidates

WRITTEN BY: Nouran Amin

In a publication in Trends in Pharmacological Sciences, a subclass of anti-aging compounds, called geroneuroprotectors (GNPs), have been identified in research to hold a potential role in slowing the aging process in mice. Since aging is the greatest risk factor for Alzheimer's disease (AD)—GNPs mays serve as a potential drug candidate.

Credit: rdmag.com

Alzheimer’s disease is a progressive neurodegenerative disease that first deteriorates memory and thinking skills and, eventually, the ability to perform simple tasks. Although losing memory is common as people grow old, it is not considered a normal part of aging.

Watch a video about how Alzheimer's changes the brain:

"The argument for geroprotectors is that if one can extend the lifespan of model organisms, such as mice, and translate this effect to humans, then you should be able to slow down the appearance of many diseases that are associated with aging, such as Alzheimer's, Parkinson's, cancer and overall frailty," states Dave Schubert, first author, Salk Institute professor and head of Salk's Cellular Neurobiology Laboratory.

In the study researchers first focused on two medicinal properties found in plants fisetin, derived from fruits and vegetables, and curcumin, from the curry spice turmeric. Researchers used these compounds, to synthesize three AD drug candidates based on their ability to protect neurons from age-related toxicities in the brain. The compounds that were then synthesized are CMS121, CAD31, and J147.

"Since we found that the natural products curcumin and fisetin are also GNPs and commercially available as supplements, they could provide some therapeutic benefits right now," says Maher.

Credit: Clarke.edu

The lab has successfully shown that these synthetic compounds were able to reduce the molecular markers of aging. The researchers were able to examine that the molecular pathways associated with the AD drug candidates are the same as well-studied synthetic compounds previously shown to extend the lifespan of many animals.

Researchers are hoping to get two GNPs, CMS121 and J147, into clinical trials once FDA has approved. The study is believed to validate the drug discovery model in the promotion of healthy aging

"If these drugs have benefits for other body systems, such as maintaining kidney function and overall muscle health, they could be used in additional ways to treat or prevent the diseases of aging," Schubert says.

Source: Trends in Pharmacological Sciences, Salk Research Institute

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 08, 2019
Drug Discovery & Development
DEC 08, 2019
How does a drug for colorectal cancer work?
Colorectal cancer is a fatal and common disease, and treatment decisions are often based on what genes have been mutated in the development of the cancer. ...
DEC 08, 2019
Technology
DEC 08, 2019
Machine-Learning and Epigenetics Drug Discovery
Machine learning is known for detecting patterns seen in complex data—such uniqueness has proven it roles in health and medicine. Now, researchers at...
DEC 08, 2019
Neuroscience
DEC 08, 2019
First Drug to Slow Progression of Alzheimer's Shows Promise
An estimated 5.8 million people living in the US have Alzheimer’s disease. Currently, no cure is available and any drugs have only been able to treat...
DEC 08, 2019
Neuroscience
DEC 08, 2019
Gene Mutation Identified that Protects Agaist Dementia
For over two decades, researchers have been studying an extended family of over 1,200 people from Columbia known for having a rare genetic mutation that le...
DEC 08, 2019
Drug Discovery & Development
DEC 08, 2019
FDA Approves New Drug for Sickle Cell Disease
Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting...
DEC 08, 2019
Neuroscience
DEC 08, 2019
Single Dose Ketamine Could Rewire Alcohol, Drug Dependance
Presentation by Tobias Stephenson about previous research exploring ketamine as an addiction treatment.    Researchers at University College Lond...
Loading Comments...